v3.26.1
Note 11 - Stock-Based Compensation (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Feb. 20, 2026
Mar. 31, 2026
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) [1]       2,448,500    
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) [1]       $ 1.33    
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)   242,284 203,051      
Proceeds from Stock Plans   $ 210 $ 141 $ 210 $ 141  
Restricted Stock [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)       5,746,000    
Lucid Diagnostics 2018 Equity Plan [Member]            
Common Stock, Capital Shares Reserved for Future Issuance (in shares)       26,603,181    
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)       1,004,590    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) 2,161,000          
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)       8,260,980    
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) $ 1.36          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) $ 0.85     $ 0.83 $ 0.93  
Lucid Diagnostics 2018 Equity Plan [Member] | Restricted Stock [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 5,746,000          
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value $ 7,800          
Lucid Diagnostics 2018 Equity Plan [Member] | Share-Based Payment Arrangement, Option [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)       10 years    
Lucid Diagnostics 2018 Equity Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche One [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage 0.33%     0.33%    
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)       1 year    
PAVmed 2014 Equity Plan [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)       523,300   523,300
PAVmed 2014 Equity Plan [Member] | Restricted Stock [Member]            
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)       50,000    
Lucid ESPP [Member]            
Common Stock, Capital Shares Reserved for Future Issuance (in shares)       3,500,000    
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)       1,662,087    
[1] Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.